MedTrace Logo

Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue

NCT07709234 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-22

No results posted yet for this study

Summary

Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.

The NEUROSTIM-LC study will evaluate the feasibility and potential effects of repeated tDCS sessions in adults with long COVID presenting fatigue and/or brain fog. Participants will receive 30 sessions of tDCS applied over the left dorsolateral prefrontal cortex. Assessments will be performed before and after the intervention to evaluate changes in quality of life, fatigue, cognitive function, brain metabolism, physical performance, autonomic function, sleep quality, psychological symptoms, respiratory function, and blood biomarkers.

Conditions

Interventions

DEVICE

Transcranial Direct Current Stimulation

Transcranial direct current stimulation will be delivered using a constant-current stimulator through surface electrodes placed over the scalp. The anode will be positioned over the left dorsolateral prefrontal cortex, corresponding to F3 according to the international 10-20 EEG system, and the cathode will be placed over the contralateral supraorbital region. Each session will be delivered at 2 mA for 20 minutes. Participants will complete 30 sessions.

Sponsors & Collaborators

  • Fundación Canaria Instituto de Investigación Sanitaria de Canarias

    collaborator OTHER

  • Canary Islands Health Service

    collaborator UNKNOWN

  • University of Las Palmas de Gran Canaria

    lead OTHER

Principal Investigators

  • Juan Francisco Vigueras, MD · Canary Islands Health Service

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-15
Primary Completion
2027-12-22
Completion
2028-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07709234 on ClinicalTrials.gov